Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.58 |
| ▸ | DRD3 | P35462 | 8/20 | 0.51 |
| ▸ | DRD4 | P21917 | 8/20 | 0.49 |
| ▸ | HTR1A | P08908 | 7/20 | 0.49 |
| ▸ | DRD1 | P21728 | 7/20 | 0.49 |
| ▸ | DRD5 | P21918 | 7/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | QDPR | P09417 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7482001 | 0.86 | QDPR (0.66) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL1531725 | 0.83 | KCNH2 (0.59) | — | |
| SCHEMBL2637025 | 0.83 | NPC1 (0.61) | DRD4 | |
| SCHEMBL18585948 | 0.83 | HDAC4 (0.50) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL6251685 | 0.83 | NPC1 (0.45) | DRD2QDPR | |
| SCHEMBL4615095 | 0.83 | NPC1 (0.45) | MGLLQDPR | |
| Hydrogen Sulfide SCHEMBL27863722 | 0.81 | KCNH2 (0.58) | — | |
| SCHEMBL17596063 | 0.80 | DRD2 (0.50) | DRD2DRD3 | |
| SCHEMBL2384566 | 0.80 | SMN1; SMN2 (0.62) | DRD2 | |
| SCHEMBL17398139 | 0.80 | ESR2 (0.55) | QDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024149080-A1 | 4-ALKOXY BENZIMIDAZOLE-6-CARBOXYLIC ACID DERIVATIVE SERVING AS GLP-1 RECEPTOR AGONIST | 中国科学院上海药物研究所 | 2024-07-18 | — | — | WO | disclosed |
| WO-2021259309-A1 | GLP-1 RECEPTOR AGONIST, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 广州市恒诺康医药科技有限公司 | 2021-12-30 | — | — | WO | disclosed |
| EP-3083595-A1 | PIPERIDINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2016-10-26 | — | — | EP | disclosed |
| US-9096500-B2 | Acyl sulfonamide compounds | PFIZER LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| WO-2015091988-A1 | PIPERIDINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2015-06-25 | — | — | WO | disclosed |
| EP-2593428-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2014-11-19 | — | — | EP | disclosed |
| US-20130109701-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20120184572-A1 | ARYL GPR119 AGONISTS AND USES THEREOF | METABOLEX, INC. | 2012-07-19 | — | — | US | disclosed |
| US-20110294836-A1 | ARYL GPR119 AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| EP-2303859-A2 | ARYL GPR119 AGONISTS AND USES THEREOF | Metabolex Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010008739-A2 | ARYL GPR119 AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184572-A1 | ARYL GPR119 AGONISTS AND USES THEREOF | GPR119, GPR27, GPR65 | DRD2 947/4885DRD3 1974/4885DRD4 2357/4885 |
| US-20130109701-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | DRD2 1081/4885DRD3 627/4885DRD4 1443/4885 |
| US-20110294836-A1 | ARYL GPR119 AGONISTS AND USES THEREOF | GPR119, GPR27, GPR65 | DRD2 947/4885DRD3 1974/4885DRD4 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.